Daniel Benten

Medicine · Health Sciences

31h-index4.9kcitations125works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease and Transplantation(35), Liver Disease Diagnosis and Treatment(28), Neuroendocrine Tumor Research Advances(26), Liver physiology and pathology(20), Organ Transplantation Techniques and Outcomes(18)

Publications124 total

WED-193 Resolution of portal hypertension by transjugular intrahepatic portosystemic shunt (TIPS) implantation reverses markers of gut-barrier dysfunction, systemic inflammation and anti-inflammatory monocyte alterations in patients with decompensated liver cirrhosis
Journal of Hepatology·2025
Recompensation of Liver Cirrhosis by <scp>TIPS</scp> Reduces Epithelial Cell Death Markers, Translating Into Improved Clinical Outcome
Liver International·2024· 1 citedOpen Access
Preoperative TIPS and in-hospital mortality in patients with cirrhosis undergoing surgery
JHEP Reports·2023· 19 citedOpen Access
Impact of portal hypertension on epithelial cell death markers in patients with decompensated liver cirrhosis
Zeitschrift für Gastroenterologie·2023
Resolution of portal hypertension by insertion of a transjugular intrahepatic portosystemic shunt (TIPS) ameliorates markers of gut barrier function, systemic hyperinflammation and reverses phenotypic alterations of monocytes in patients with decompensated liver cirrhosis
Zeitschrift für Gastroenterologie·2023· 1 cited
Preoperative transjugular intrahepatic portosystemic shunt and in-house mortality in patients with liver cirrhosis undergoing surgery
Journal of Hepatology·2023
Figure S6 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Supplementary Methods from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Figure S1 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Figure S3 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Figure S5 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Supplementary Methods from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Figure S4 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Figure S2 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Figure S2 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Figure S3 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Figure S6 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Figure S5 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Ansgar W. Lohse(15), Sanjeev Gupta(12), François Durand(8), Pere Ginès(8), Brigid Joseph(8), Richard Moreau(6), Marco Pavesi(6), Carlo Alessandria(6), Jonel Trebicka(6), Faouzi Saliba(6), Thierry Gustot(6), Mauro Bernardi(6), Vicente Arroyo(6), Vinay Kumaran(6), Rudolf Stauber(5), Minneke J. Coenraad(5), Jörg Schrader(5), Paolo Caraceni(5), Mari Inada(5), Antonia Follenzi(5)